en.Wedoany.com Reported - Xutong Technology (Fujian) Co., Ltd. has officially launched its deeply customized "αBlood AI All-in-One Machine." This device was created to address the dual challenges of efficiency and safety in the clinical blood use sector, marking the full-stack domestic implementation of artificial intelligence in the critical field of blood management, which directly impacts people's livelihoods.
For a long time, the entire process from blood collection, testing, and storage to distribution and clinical application has been highly complex with an extremely low margin for error. Wang Jingquan, Director of Xutong Technology, has publicly pointed out that blood demand under traditional working models primarily relies on manual estimation, which is not only extremely labor-intensive but also struggles to achieve precision and efficiency.
To overcome this structural challenge, Xutong Technology has engaged in deep cooperation with ecosystem partners like Huawei, integrating the powerful computing capabilities of Huawei's Ascend chips with domestic large model technology. The all-in-one machine embeds a blood-specific vertical large model trained on the massive industry data from Chuanyue Medical. Unlike general-purpose AI, this "AI Blood Expert" is deeply rooted in the underlying data logic of the medical industry, capable of rapidly analyzing a hospital's historical blood usage patterns, seasonal disease outbreak curves, real-time dynamic inventory status, and regional differences in medical demand. Through deep reasoning over this multi-source heterogeneous information, αBlood can automatically generate highly scientific blood use plans and full-chain inventory optimization solutions.
The leap in performance data is the most intuitive measure of its implementation value. Public data disclosed by Xutong Technology shows that in actual deployments at blood stations or transfusion departments of large hospitals, the αBlood AI All-in-One Machine can complete complex full-process calculations that previously took a long time in just 10 to 15 minutes, and its decision-making accuracy is improved by over 90% compared to traditional manual experience-based methods.
Wang Jingquan particularly emphasized the strategic significance of this launch's domestic localization. "The αBlood AI All-in-One Machine is entirely independently developed by Xutong Technology, achieving 100 percent domestic production." He pointed out that after a decade of sustained investment and technical research, the team has successfully achieved the domestic substitution of a full series of key equipment in this field. This not only breaks the long-standing heavy reliance on foreign underlying software and hardware in the field of blood information management, fundamentally solving the supply chain constraints faced by China in critical key technologies for blood, but also safeguards national biosecurity and the absolute privacy of public health data with an autonomous, secure, and controllable computing base. Currently, this device has been selected as one of the Top Ten Solutions of the 2025 Artificial Intelligence Independent Innovation Consortium.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
